We are going to take a deep look at Pfizer Inc. (NYSE:PFE) to get a better view of the company and its prevailing status, as well as the prospect it may offer for investors. Today’s prime focus will be a fundamental assessment of the equity from top to bottom.
As such, let’s begin with the top line, i.e. revenue trends. Last quarter, the firm saw its overall revenue come at $13.3B. That represents a change in revenues, on a quarterly/yearly basis, of 0.01%. If it is translated into sequential terms, the firm witnessed sales decline by -0.01% from quarter to quarter.
It’s important to track the top line data. There’s no better way to compute the end market’s reception of a firms products. But no one wins without bottom line performance, which is what is required to look at next. Pfizer Inc. (NYSE:PFE) is intriguing when segregated to its core data. The cost of selling goods in preceding quarter was $3.93B, resulting in a gross basic income of $9.37B. For shareholders, provided the total diluted due shares of 5.99B, this means earnings per share of $0.69. Note, this assesses with a consensus analyst projection of $0.83 in EPS for its next quarterly report.
Given that data, now is the time to turn to a thorough glance across analyst projections for the firm going forward. At present, analysts have a consensus average recommendation of Overweight. This is grounded on a total of 16 analysts. While we don’t recommend taking analyst calls as face value strategies for action in a portfolio, we do consider it is vital to note where consensus is on equity to understand what basic assumptions are possibly already discounted into the pricing of shares. As far as price targets, market analysts have an average target of $46.32. In addition, for next year, estimates of a fiscal year forecast are 3.08 in total EPS. On a median price to earnings ratio, that outlook results in a valuation of $14.07 times earnings.
For Pfizer Inc. (NYSE: PFE), the firm presently holds around $3.56B in cash. That cash is balanced against around $7.39B in total current liabilities. The firm’s debt is $falling, while total assets are $167.84B balanced by total liabilities of $96.17B. The free cash flow last quarter was $4.71B, representing a net change in cash of $848M. On a net operating level, the cash flow was about $5.26B.
Let’s take a look at the technical analysis. The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak.
We will apprise the interesting story of Pfizer Inc. (NYSE: PFE) as new events transpire.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE